SCHEMBL25201508

SCHEMBL25201508

CC(C)(C)OC(=O)C(N)C1CC(N)C1

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.34
NOS3 P29474 1/20 0.34
NOS2 P35228 1/20 0.34
DPP4 P27487 2/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25201507 1.00 NOS1 (0.34) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL26091132 0.85 CHRM2 (0.42) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL26091128 0.85 CHRM2 (0.42) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL8487787 0.84 DPP4 (0.40) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL3187231 0.84 DPP4 (0.40) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL14978004 0.82 DPP4 (0.36) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL31564804 0.82 DPP4 (0.36) NOS1NOS3NOS2DPP4CHRM2
SCHEMBL27570839 0.79 DPP4 (0.41) DPP4
SCHEMBL12374491 0.78 DPP4 (0.44) DPP4
SCHEMBL4116106 0.78 NOS1 (0.34) NOS1NOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019376-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2025-01-16 US disclosed
EP-4433476-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS Merck Sharp & Dohme LLC (US) 2024-09-25 EP disclosed
CN-118265711-A Chromanamidine monocyclic lactam antibiotics 默沙东有限责任公司 2024-06-28 CN disclosed
US-11932637-B2 Chromane amidine monobactam compounds for the treatment of bacterial infections MERCK SHARP & DOHME LLC (US) 2024-03-19 US disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed
WO-2023091438-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2023-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM NOS1 1926/4885NOS3 2961/4885NOS2 2124/4885
US-20250019376-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS PAM, ACMSD, MGAM2 NOS1 976/4885NOS3 2182/4885NOS2 1288/4885
US-11932637-B2 Chromane amidine monobactam compounds for the treatment of bacterial infections MGAM, MGAM2, ELANE NOS1 665/4885NOS3 1893/4885NOS2 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.